Home > Healthcare > Pharmaceuticals > Finished Drug Form > Retinal Vein Occlusion (RVO) Treatment Market

Retinal Vein Occlusion (RVO) Treatment Market Share

Report ID: GMI9772
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Retinal Vein Occlusion Treatment Market Share

The competitive landscape of the market is characterized by the presence of several key players striving to address the growing demand for effective therapies. The companies are focusing on innovative RVO treatment options, including anti-VEGF drugs, corticosteroids, and surgical interventions. These companies are investing heavily in R&D to enhance treatment efficacy and expand their product portfolios. Moreover, strategic collaborations, mergers, and acquisitions are common tactics employed to strengthen market presence and gain a competitive edge.

Retinal Vein Occlusion Treatment Market Companies

Few of the prominent players operating in the retinal vein occlusion treatment industry include:

Allergan, Inc.
Aerie Pharmaceuticals Inc.
Bayer AG
Biocon Biologics Ltd
Chugai Pharmaceutical Co., Ltd.
Coherus BioSciences, Inc.
EyePoint Pharmaceuticals Inc.
Genentech Inc. (F. Hoffmann-La Roche Ltd.)
Novartis AG
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co., Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Retinal vein occlusion treatment market size was USD 2.2 billion in 2023 and is expected to register 5.8% CAGR from 2024-2032 owing to the rising prevalence of diabetes and hypertension worldwide.

Retinal vein occlusion treatment industry from the CRVO segment is expected to register 5.7% CAGR from 2024-2032 due to the complications associated with the condition leading to the need for an effective therapy.

The U.S. retinal vein occlusion treatment industry reached USD 858.5 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the high prevalence of diabetes and hypertension which are major risk factors for RVO in the region.

Bayer AG, Chugai Pharmaceutical Co., Ltd., Coherus BioSciences, Inc., EyePoint Pharmaceuticals Inc., Genentech Inc. (F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc, and Samsung Bioepis Co., Ltd., are some of the major retinal vein occlusion treatment worldwide.